Heart failure & cardiomyopathiesCohort study
Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure
- Prospective cohort study
Authors' conclusion
Systemic thromboxane A2 generation as measured by urinary TXB2-MGFR was significantly associated with HF risk and remained so after accounting for traditional risk factors.
Study context
- Population
- Framingham Heart Study participants without prior heart failure (HF) and with left ventricular ejection fraction (LVEF) ≥55%, irrespective of ASA use
- Participants
- 2,611 participants
- Exposure
- High vs low urinary TXB2-MGFR
- Outcome
- Incident HF
- Follow-up
- Median 14.8 years (Q1-Q3: 12.6-15.7 years)
Main finding
As reported in the abstract
Hazard ratio
1.81
95% CI 1.38–2.64
P < 0.0001
High TXB2-MGFR vs Low TXB2-MGFR
HR 1.81 (95% CI 1.38–2.64); P < 0.0001
- HF occurred overall
- 189 participants (7.2%)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| HF with preserved LVEF · adjusted for age, sex, ASA use, and CVD | 1.81 (1.17–2.80) | P = 0.0081 | |
| HF with reduced LVEF · adjusted for age, sex, ASA use, and CVD | 2.63 (1.48–4.68) | P = 0.0010 | |
| 0.20.5125Hazard ratio (log scale) |
- HF with preserved LVEF — First HF events with preserved LVEF
- 104 (55.0%)
- HF with reduced LVEF — First HF events with reduced LVEF
- 56 (29.6%)
ASA use and plasma P-selectin
- Neither ASA use nor platelet activation (plasma P-selectin) independently associated with HF risk
Original publication
Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure. J Am Coll Cardiol. Published 7 January 2025. doi:10.1016/j.jacc.2024.09.010
Summarised from the published abstract; every number is checked against it